BofA/Merrill Lynch downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Buy to Underperform with a price target of $15.00 (from $20.00).Analyst Ying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE